Germany at a glance
- Population
- 83.5 million 2025
- Life expectancy at birth
- 80.8 years, 2024
- People aged 65 and over
- 23.7 % of people, 2025
- Health spending per person
- 6,849 US$ per person, 2024
- Doctors
- 4.53 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
Germany Pain Management Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Pain Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$789.3 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $3.09 Bn | — | — |
| 2025 (base) | $3.17 Bn | +$77.4 Mn | — |
| 2026 (forecast) | $3.25 Bn | +$79.3 Mn | +2.5% |
| 2027 (forecast) | $3.33 Bn | +$81.3 Mn | +5.1% |
| 2028 (forecast) | $3.42 Bn | +$83.3 Mn | +7.7% |
| 2029 (forecast) | $3.50 Bn | +$85.4 Mn | +10.4% |
| 2030 (forecast) | $3.59 Bn | +$87.5 Mn | +13.1% |
| 2031 (forecast) | $3.68 Bn | +$89.7 Mn | +16% |
| 2032 (forecast) | $3.77 Bn | +$92.0 Mn | +18.9% |
| 2033 (forecast) | $3.86 Bn | +$94.3 Mn | +21.8% |
| 2034 (forecast) | $3.96 Bn | +$96.6 Mn | +24.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $3.17 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $3.96 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 2.5% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Analgesics |
| Segments | Drug class, pain type and end user (see all) |
| Key players | Pfizer Inc., Johnson & Johnson, Haleon PLC, Purdue Pharma, Vertex Pharmaceuticals (see all) |
| Regulator in Germany | BfArMSource: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Pain management drugs relieve acute and chronic pain, from over-the-counter painkillers to prescription medicines.
Key segments of the pain Management Drugs market include drug class (NSAIDs, Opioids and Anticonvulsants) and pain type (Acute, Chronic and Cancer Pain).
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the pain Management Drugs market.
Ready-to-use formulations, biosimilars and supply security programmes give the pain Management Drugs market room to grow.
Drug shortages, price controls, generic competition and strict hospital budgets hold back the pain Management Drugs market.
The pain Management Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut.[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.[2]
[1] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[2] Federal Joint Committee (G-BA). Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pain Management Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.
What doctors and scientists are doing in Pain Management Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
Germany · 2 shared keywords
Germany · 2 shared keywords
Germany · 1 shared keyword
Germany · 1 shared keyword
Germany · 1 shared keyword
Germany · 1 shared keyword
OTC & Nutraceuticals · Germany
Medical Devices · Germany
Medical Devices · Germany
Public Health · Global